Geovax Labs, INC. 8-K Filing
Ticker: GOVX · Form: 8-K · Filed: Nov 26, 2025 · CIK: 832489
Sentiment: neutral
Filing Stats: 767 words · 3 min read · ~3 pages · Grade level 12.1 · Accepted 2025-11-26 16:05:50
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share GOVX The Nasdaq Capital Ma
Filing Documents
- govx20251126_8k.htm (8-K) — 27KB
- 0001437749-25-036447.txt ( ) — 154KB
- govx-20251126.xsd (EX-101.SCH) — 3KB
- govx-20251126_def.xml (EX-101.DEF) — 11KB
- govx-20251126_lab.xml (EX-101.LAB) — 15KB
- govx-20251126_pre.xml (EX-101.PRE) — 11KB
- govx20251126_8k_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held a special meeting of stockholders on November 26, 2025. The Company received proxies totaling 14,125,083 of its 29,705,360 issued and outstanding shares of common stock as of the record date of September 30, 2025. The stockholders voted on the following proposals and the results of the voting are presented below. Approval of the September 2025 Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 11,904,768 shares of our common stock upon exercise of common stock purchase warrants issued to certain institutional investors in connect with the private placement offering which occurred on September 30, 2025. There were 6,501,642 broker non-votes on this item. For Against Abstain 5,806,374 946,094 870,973 Reverse Stock Split Our stockholders approved an amendment to our Certificate of Incorporation to effect a reverse stock split of our issued and outstanding common stock at a ratio of not less than 1-for-10 and not greater than 1-for-25, such ratio to be determined by our Board of Directors. There were no broker non-votes on this item. For Against Abstain 11,850,760 2,158,471 115,852
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 26, 2025 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer 3